GPX4-IN-3|cas:2761004-85-5|西域试剂

GPX4-IN-3,99.69%

产品编号：Bellancom-141809| CAS NO：2761004-85-5| 分子式：C₂₉H₂₄ClN₃O₃S| 分子量：530.04

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-141809	￥3900.00	杭州北京（现货）
Bellancom-141809	￥6500.00	杭州北京（现货）
Bellancom-141809	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GPX4-IN-3

产品介绍

GPX4-IN-3 (26a) 是有效的谷胱甘肽过氧化物酶4 (GPX4) 抑制剂，可选择性诱导铁死亡 (ferroptosis)。GPX4-IN-3 (26a) 在1 μM 的浓度可抑制GPX4 71.7% 活性。

生物活性

GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM.

体外研究

GPX4-IN-3 (26a) exhibits IC₅₀ values of 0.78 μM, 6.9 μM, 0.15 μM and 4.73 μM in 4T1, MCF-7, HT1080 and HT1080 (with Fer-1) cells, respectively.
GPX4-IN-3 (26a) exhibits outstanding GPX4 inhibitory activity with a percent inhibition up to 71.7% at 1.0 μM compared to 45.9% of RSL-3.
GPX4-IN-3 (26a) could significantly induce lipid peroxide (LPO) increase and effectively induce ferroptosis with satisfactory selectivity.
GPX4-IN-3 (26a) is more likely to induce ferroptosis through the accumulation of intracellular peroxides via inhibiting GPX4 activity.
GPX4-IN-3 (26a) significantly increased the level of ROS in 4T1 cells, which could also be reversed by Ferrostatin-1 (fer-1).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

GPX4-IN-3 (26a) exertes antitumor activity and good biological safety in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse 4T1 xenograft model.
Dosage:	15 and 30 mg/kg.
Administration:	Intravenous injection, every two days for a total of five times.
Result:	Significantly suppress tumor growth with a tumor growth inhibition (TGI) value of 33.2 and 55.1% at 15 and 30 mg/kg, respectively.

体内研究

GPX4-IN-3 (26a) exertes antitumor activity and good biological safety in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse 4T1 xenograft model.
Dosage:	15 and 30 mg/kg.
Administration:	Intravenous injection, every two days for a total of five times.
Result:	Significantly suppress tumor growth with a tumor growth inhibition (TGI) value of 33.2 and 55.1% at 15 and 30 mg/kg, respectively.

性状

Solid

溶解性数据

In Vitro:

DMSO : 67.5 mg/mL (127.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8867 mL	9.4333 mL	18.8665 mL
5 mM	0.3773 mL	1.8867 mL	3.7733 mL
10 mM	0.1887 mL	0.9433 mL	1.8867 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 6.75 mg/mL (12.73 mM); Suspended solution; Need ultrasonic

此方案可获得 6.75 mg/mL (12.73 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 67.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 6.75 mg/mL (12.73 mM); Clear solution

此方案可获得 ≥ 6.75 mg/mL (12.73 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 67.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。